WT1 and acute myeloid leukemia: A vaccine made of two distinct WT1 HLA-A2-restricted epitopes and HLA-DR T helper cell epitope (PADRE) was administered in 8 HLA-A*0201-positive patients with poor-risk AML at different stages of disease.